Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan with VIT for Pediatric Solid Tumors
NCT06710821Phase 1Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of nanoliposomal irinotecan in solid tumor. Primary endpoint: Maximum Tolerated Dose at 6 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06710821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710821.